Nektar Therapeutics priced an upsized $325 million public offering of 3,532,609 shares at $92.00 per share, expected to close April 23, 2026.23
Underwriters have a 30-day option to purchase up to 529,891 additional shares.23
Proceeds will fund general corporate purposes, including Phase 3 trials and manufacturing for rezpegaldesleukin in atopic dermatitis and alopecia areata.26
No recent news found on Maze stock rises, Merck deal rumors, or BMS layoffs in provided results.
Sources:
2. https://www.stocktitan.net/news/NKTR/nektar-therapeutics-announces-pricing-of-upsized-325-million-public-6zypsbvhu0q9.html
3. https://intellectia.ai/news/stock/nektar-therapeutics-prices-upsized-325m-public-offering
6. https://www.investing.com/news/company-news/nektar-prices-325m-stock-offering-at-92-per-share-93CH-4628008